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ARMYDA-9 CAROTID: Clopidogrel Load & 
Atorvastatin Reload Prevent Ischemic Cerebral 
Events After Protected Carotid Stenting 
A total of 156 patients undergoing protected carotid 
stenting were randomized to a 600-mg (n=78) or 300-mg 
(n=78) clopidogrel load given 6 h before intervention and 
either an atorvastatin reload (n=76; 80 mg + 40 mg 
initiating 12 h before the procedure) or no statin reload 
(n=80). Occurrence of the primary outcome (30-day 
incidence of TIA/stroke or new ischemic lesions on 
cerebral MRI performed at 24-48 h) was lower in the 
600-mg clopidogrel arm (18% vs. 35.9% in the 300-mg 
group; p = 0.019) and in the atorvastatin reload arm 
(18.4% vs 35.0% in the no statin reload group; p=0.031). 
High-dose clopidogrel also significantly reduced the TIA/ 
stroke rate at 30 days (0% vs 9%, p = 0.02), without an 
increase in bleeding risk. The authors concluded that in 
patients undergoing carotid stenting, a 600-mg clopido-
grel load and a short-term reload with high-dose atorva-
statin protects against early ischemic cerebral events 
(Patti G et al, J Am Coll Cardiol 2013;61:1379-1387)  
 
MADIT CRT: Carvedilol Produces 30% Reduction in 
Hospitalizations for HF or Death When Compared 
With Metoprolol 
The effects of metoprolol and carvedilol were 
compared in the MADIT-CR study. Hospitalization for 
HF or death occurred in 23% on carvedilol and 30% on 
metoprolol (hazard ratio-HR: 0.70, p=0.001), further 
attenuated in the subgroup of CRT-D patients (HR: 0.61, 
p = 0.001) and CRT-D patients with LBBB (HR: 0.51, p 
< 0.001). Ventricular arrhythmias occurred in 22% and in 
26%, respectively, of the patients receiving carvedilol or 
metoprolol (HR: 0.80, p = 0.050). A dose-dependent 
relationship was found in carvedilol, but not in 
metoprolol. The authors concluded that in HF patients in 
NYHA class I/II & wide QRS, carvedilol was associated 
with a 30% reduction in hospitalizations for HF or death 
when compared with metoprolol. A novel beneficial and 
synergistic effect of carvedilol was seen in patients with 
CRT-D & LBBB. Finally, a dose-dependent effect was 
apparent in carvedilol, but not in metoprolol (Ruwald et 
al, J Am Coll Cardiol 2013;61:1518–1526).  
 
Colchicine Reduces In-Stent Restenosis (ISR) in 
Diabetic Patients Receiving a Bare-Metal Stent 
 A total of 196 diabetic patients, aged 64+7 years, with 
contraindication to a drug-eluting stent, undergoing PCI 
with a bare-metal stent (BMS), were randomized to 
receive colchicine 0.5 mg twice daily or placebo for 6 
months. The angiographic in-stent restenosis (ISR) was 
16% in the colchicine group and 33% in the control group 
(p = 0.007; odds ratio: 0.38). The number needed to treat 
to avoid 1 case of angiographic ISR was 6. The results 
were similar for IVUS-defined ISR (odds ratio: 0.42; 
number needed to treat = 5). Lumen area loss was 1.6 
mm2 in colchicine-treated patients and 2.9 mm2 in the 
control group (p = 0.002). Adverse events from 
colchicine were limited to gastrointestinal symptoms. The 
authors concluded that colchicine is associated with less 
neointimal hyperplasia and decreased ISR in diabetic 
patients after PCI with a BMS (Deftereos S et al, J Am 
Coll Cardiol 2013;61:1679–1685). 
 
Cryoballoon PVI Comparable to RFC Ablation in AF 
Cryoballoon ablation was used for pulmonary vein 
isolation (PVI) in 605 patients with paroxysmal (n=579) 
or persistent (n=26) AF. PVI was achieved in 91%. At 
median follow-up of 30 months (n=451), 278 (~62%) 
patients were free of AF recurrence with no need for 
repeat procedures. Rates of freedom from AF after 1, 2, 
& 3 repeat procedures (using cryoballoon and/or radiofre-
quency catheter-RFC ablation) were 75%, 76%, and 77%, 
respectively. Use of the smaller balloons or both balloons 
produced the highest rates of long-term freedom from 
AF. Phrenic nerve palsy was noted in 12 patients (2%), 
resolving within 3-9 months. The authors concluded that 
long-term freedom from AF after cryoballoon ablation is 
similar to that reported for radio-frequency ablation. A 
choice between balloons may improve outcomes (Vogt et 
al, J Am Coll Cardiol 2013;61:1707–1712).  
 
STO-AF Trial: Cryoballoon Ablation a Safe and 
Effective Alternative to Antiarrhythmic Drugs for 
Symptomatic Paroxysmal AF 
Patients with symptomatic paroxysmal AF and 
previously failed drug therapy underwent 2:1 
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randomization to either cryoballoon ablation (n=163) or 
drug therapy (n=82). In 160 (98.2%) patients, 3 or more 
pulmonary veins (PVs) were isolated. All 4 major PVs 
were isolated in 97.6% of patients, as were 21 of 21 left 
common PVs and 10 of 13 right middle PVs. In 83% of 
patients, cryoballoon alone was sufficient for PV isolation 
(PVI). At 12 months, treatment success was 70% 
compared with 7.3% of antiarrhythmic drug patients. 
Sixty-five (79%) drug-treated patients crossed over to 
cryoablation during 12 months of study follow-up due to 
recurrent, symptomatic AF. Twenty-nine of 259 
procedures (11.2%) were associated with phrenic nerve 
palsy; 25 of these had resolved by 12 months. 
Cryoablation patients had significantly improved 
symptoms at 12 months. The authors concluded that 
cryoballoon ablation is a safe and effective alternative to 
antiarrhythmic medication for patients with symptomatic 
paroxysmal AF, for whom at least one drug has failed, 
with acceptable risks (Packer et a, J Am Coll Cardiol 
2013;61: 1713–23).  
 
Substitution of Prasugrel for Clopidogrel in Patients 
on Triple Therapy Increases the Risk of Bleeding  
About 10% of patients who receive dual antiplatelet 
therapy after PCI have an indication for oral 
anticoagulation. In a consecutive series of 377 patients 
who underwent PCI with DES and had an indication for 
oral anticoagulation were treated with a 6-month regimen 
of aspirin and oral anticoagulation with either prasugrel 
or clopidogrel. A total of 21 patients (5.6%) received 
prasugrel instead of clopidogrel. TIMI major and minor 
bleeding occurred significantly more often in the 
prasugrel compared with the clopidogrel group: 6 
(28.6%) vs. 24 (6.7%); adjusted hazard ratio (HR): 3.2, p 
= 0.03). There was no significant difference regarding the 
secondary endpoint (composite of death, myocardial 
infarction, ischemic stroke, or definite stent thrombosis): 
2 (9.5%) vs. 25 (7.0%). The authors concluded that 
substitution of prasugrel for clopidogrel in patients 
needing triple therapy increases the risk of bleeding 
(Sarafoff et al, J Am Coll Cardiol 2013;61:2060–2066).  
 
CARE-HF Trial: RV Dysfunction (TAPSE <14 mm) is 
a Prognostic Determinant Among CRT Patients 
Of 813 patients in the CARE-HF trial, 688 had 
tricuspid plane systolic excursion (TAPSE) measured at 
baseline, and 345 of them were assigned to CRT. Median 
age was 66 years, LVEF 24%, and TAPSE 19 mm. Those 
with worst TAPSE (<17.4 mm) were more likely to have 
ischemic heart disease. Overall, CRT improved LV but 
not RV structure and function. At median follow-up of 2 
years, 213 deaths occurred. Patients with lower TAPSE 
had a higher mortality, regardless of assigned treatment 
(p<0.001). Greater inter-ventricular delay, NYHA class, 
mitral regurgitation, and NT pro–B-NP, lower TAPSE, 
and assignment to control group were independently 
associated with higher mortality. Reduction in mortality 
with CRT was similar in each tertile of TAPSE. The 
authors concluded that right ventricular (RV) dysfunction 
is a powerful determinant of prognosis among candidates 
for CRT, regardless of treatment assigned, but did not 
diminish the benefit of CRT (Damy et al, J Am Coll 
Cardiol 2013;61:2153–2160).  
 
“Real-World” Experience With Dabigatran: No 
Evidence of Excess Bleeding or MI 
Concerns have been raised about an excess of 
bleeding or myocardial infarction (MI) among patients 
treated with dabigatran. From a Danish Registry, a 
dabigatran-treated group (n=4978) and a 1:2 propensity-
matched warfarin-treated group (n=8,936) were 
compared. Stroke and systemic embolism were not 
significantly different between the 2 groups. Adjusted 
mortality was significantly lower with both dabigatran 
doses (110 mg bid, hazard ratio-HR: 0.79; 150 mg bid, 
HR: 0.57). Pulmonary embolism was lower compared 
with warfarin for both doses of dabigatran. Less 
intracranial bleeding was seen with both dabigatran doses 
(110 mg, HR: 0.24; 150 mg, HR: 0.08). The incidence of 
MI was lower with both dabigatran doses (110 mg, HR: 
0.30; 150 mg, HR: 0.40). Gastrointestinal bleeding was 
lower with the lower dose of dabigatran 110 mg (HR: 
0.60) but not with the higher dose. The authors concluded 
that in this “everyday clinical practice”, there were 
similar stroke/systemic embolism and major bleeding 
rates with both doses of dabigatran compared with 
warfarin. Mortality, intracranial bleeding, pulmonary 
embolism, and MI were lower with dabigatran, compared 
with warfarin (Larsen et al, J Am Coll Cardiol 
2013;61:2264–2273) 
 
Direct Transaortic Approach for TAVI is Feasible  
Initial US experience with direct transaortic approach 
to transcatheter aortic valve implantation (TAVI) was 
reported in 44 patients with inoperable, severe aortic 
stenosis, ineligible for transfemoral access. Data were 
compared with those from 76 patients who underwent 
transapical TAVI. Device implantation success (89% vs. 
84%) and 30-day combined safety endpoint of all-cause 
mortality, MI, major stroke, disabling bleeding, severe 
acute kidney injury, and valve reintervention (20% vs. 
33%) were similar. The transaortic approach was 
associated with lower combined bleeding and vascular 
event rate (27% vs. 46%; p = 0.05), shorter median ICU 
stay (3 vs. 6 days; p = 0.01), and a favorable learning 
curve. The authors concluded that the transaortic 
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approach is technically feasible and seems to be 
associated with favorable outcome (Lardizabal et al, J 
Am Coll Cardiol 2013;61:2341–5).  
 
Northern Manhattan Study (NOMAS): Incidentally 
Detected PFO by Transthoracic Echocardiography 
has Very Low Prevalence and is not Associated With 
an Increased Risk of Clinical or Subclinical Stroke 
 
Patent foramen ovale (PFO) presence was assessed by 
transthoracic echocardiography with saline contrast 
injection in 1,100 stroke-free individuals aged >39 of a 
community-based sample followed for a mean of 11 
years. Also, 360 participants had MRI for silent brain 
infarct (SBI) detection. PFO was present in 164 (14.9%). 
Over a mean follow-up of 11.0 + 4.5 years, 111 ischemic 
strokes occurred (10.1%), 15 (9.2%) in the PFO and 96 
(10.3%) in the non-PFO group. The 12.5-year cumulative 
risk of stroke was 10.1% in the PFO and 10.4% in the 
non-PFO group (p=NS). The adjusted hazard ratio for 
PFO and stroke was 1.10. In the MRI subcohort, PFO 
was not associated with SBI. The authors concluded that 
in this community-based cohort, PFO was not associated 
with an increased risk of clinical or subclinical stroke (Di 
Tullio et al, J Am Coll Cardiol 2013;62:35–41).  
 
Pregnancy Loss is Associated With an Increased Risk 
of MI, Stroke, and Renovascular Hypertension: A 
Possible Risk Factor for Atherosclerotic Disease in 
Women?  
 
Among women pregnant at least once, a cohort of 
women was identified with miscarriages, stillbirths, or 
live singleton births. Among 1,031,279 such women 
followed for an average of 15 years per woman, 2798 
myocardial infarctions (MIs), 4053 strokes, and 1269 
cases of renovascular hypertension were detected. 
Women with stillbirths had 2.7, 1.7, and 2.4 times the 
rates of MI, strokes, and renovascular hypertension, 
respectively, as women with no stillbirths. Compared 
with women with no miscarriages, women with 
miscarriages had 1.13, 1.16, and 1.20 times the rates of 
these same outcomes, respectively; these associations 
were dose dependent, with each additional miscarriage 
increasing the rates of MI, strokes and renovascular 
hypertension by 9%, 13%, and 19%, respectively. 
Associations were strongest in younger women (<35 
years). The authors concluded that pregnancy losses were 
associated with subsequent risks of MI, strokes, and 
renovascular hypertension, conditions linked to 
atherosclerosis, making pregnancy loss a possible 
candidate risk factor for atherosclerotic disease in 
women, with possible inflammatory processes being the 
common denominator (Ranthe et al, Circulation 
2013;127:1775-1782).  
 
Swedish Study: AF is an Independent Risk Factor of 
All-Cause Mortality in Patients Hospitalized With 
Incident AF and Relative Risk is Higher in Women 
and Highest in the Youngest Patients  
 
A total of 272,186 patients (≤85 years; 44% women) 
hospitalized with incidental AF (1995–2008) and 544,344 
matched controls were compared. The adjusted long-term 
relative all-cause mortality risk in women vs. controls 
was 2.15, 1.72, and 1.44 (P<0.001) in the age categories 
≤65, 65–74, and 75–85 years, respectively. These figures 
for men were 1.76, 1.36, and 1.24 (P<0.001). Among 
comorbidities, neoplasm, chronic renal failure, and 
chronic obstructive pulmonary disease contributed most 
to the increased mortality vs. controls. In patients with 
AF as the primary diagnosis, the relative risk of mortality 
was 1.63, 1.46, and 1.28 (P<0.001) in women and 1.45, 
1.17, and 1.10 (P<0.001) in men. The authors concluded 
that AF was an independent risk factor of all-cause 
mortality in patients with incident AF. Although the 
actual risk was consistently lower in women, the highest 
relative risk of mortality was seen in women and in the 
youngest patients compared with controls (Andersson et 
al, Eur Heart J 2013;34:1061–1067) 
 
AFFIRM Study/ Propensity-Adjusted Analysis: 
Increased Mortality Among Patients Taking Digoxin 
The association between digoxin and mortality was 
assessed in patients enrolled in the AFFIRM trial. 
Analyses were conducted in all patients and in subsets 
according to the presence or absence of heart failure 
(HF). Digoxin was associated with an increase in all-
cause mortality (hazard ratio-HR 1.41; P<0.001), 
cardiovascular mortality (HR 1.35, P = 0.016), and 
arrhythmic mortality (HR 1.61, P = 0.009). The all-cause 
mortality was increased with digoxin in patients without 
or with HF. There was no significant digoxin–gender 
interaction for all-cause or cardiovascular mortality. The 
authors concluded that digoxin was associated with a 
significant 41% increase in all-cause mortality in patients 
with AF after correcting for clinical characteristics and 
comorbidities, regardless of gender or of the presence or 
absence of HF (Whitbeck et al, Eur Heart J 2013;34: 
1481-1488).  
 
AFFIRM Study/ Post Hoc Propensity-Matched 
Analysis: Lack of Evidence of Increased Mortality 
Among Patients Taking Digoxin 
 
In the AFFIRM study, 4060 patients with paroxysmal 
and persistent AF were randomized to rate (n=2027) vs. 
rhythm (n=2033) control strategies. Of these, 1377 
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received digoxin as initial therapy. A cohort was 
assembled of 878 pairs of patients receiving and not 
receiving digoxin, who were balanced on baseline 
characteristics. During the 3.4 years of the mean follow-
up, all-cause mortality occurred in 14 and 13% of 
matched patients receiving and not receiving digoxin, 
respectively (hazard ratio-HR associated with digoxin 
use: 1.06; P = NS). Also, no association with all-cause 
hospitalization or incident non-fatal cardiac arrhythmias 
could be found. The authors concluded that in patients 
with paroxysmal and persistent AF, no evidence was 
found of increased mortality or hospitalization in those 
taking digoxin as baseline initial therapy (Gheorghiade et 
al, Eur Heart J 2013;34:1489-1497). 
 
The Post-Hoc Non-Randomized Observational Design 
of Both the AFFIRM Trial Analyses May Explain the 
Conflicting Results About the Risk of Digoxin  
 
The editorial comments that accompany the above 2 
studies, which are two different analyses of the AFFIRM 
trial, point to the different design of the studies in order to 
explain the conflicting results of analysis of the same 
data. The first editorial indicates that “In the article by 
Whitbeck et al, digoxin use was assessed at 
randomization and during follow-up. The association of 
digoxin use with mortality was evaluated treating digoxin 
as a time-dependent covariate in a Cox proportional 
hazard model. By using digoxin as a time-dependent 
covariate, patients changed from being in the ‘on-
digoxin’ group to the ‘not on-digoxin’ group if their 
medication use changed over time in the study, and their 
associated time at risk for death contributed to each 
respective group”. On the other hand “In the article by 
Gheorghiade et al, digoxin use was assessed at a fixed 
time point only, at the time of randomization”. The first 
commenter concludes that “Given the non-randomized, 
observational design of both studies, the findings should 
be considered hypothesis generating. Even sophisticated 
statistical methods such as propensity analysis cannot 
replace randomization” (Murphy S, Eur Heart J 
2013;34:1465-1467).  
The commenters in the second editorial also point to 
the post hoc and non-randomized design of the analyses, 
but focus on the high dose of digoxin used indicating that 
“patients in AFFIRM were receiving high doses of 
digoxin, since they were encouraged to have an serum 
level ≥1.0 ng/mL”, which “may have contributed to the 
observed increased mortality”. Their concluding remark 
is that “With regard to the place of digoxin in AF, it is 
likely that this will further diminish in the future, because 
of its inefficacy to reduce heart rate during exercise on 
the one hand, and the outcome of studies such as the 
study of Whitbeck et al”, albeit “low-dose digoxin may 
still be useful, but trials examining this question are 
urgently needed” (van Veldhuisen et al, Eur Heart J 
2013;34:1468-1470).   
 
Adding a New Oral Anticoagulant to Antiplatelet 
Therapy Results in a Modest Reduction in Cardio-
vascular Events but a Substantial Increase in Bleeding  
 
A meta-analysis was performed of 7 randomized 
studies evaluating the efficacy and safety of adding a 
novel oral anticoagulant to single (aspirin) or dual 
(aspirin and clopidogrel) antiplatelet therapy in patients 
with acute coronary syndromes (ACS). The analysis 
comprised 30 866 patients, 4135 (13.4%) on single, and 
26 731 (86.6%) on dual antiplatelet therapy, with an ACS 
within the last 7–14 days. When compared with aspirin 
alone, the addition of an oral anticoagulant reduced the 
incidence of major adverse cardiac events (MACE) 
(hazard ratio-HR 0.70), but increased clinically 
significant bleeding (HR: 1.79). Compared with dual 
antiplatelet therapy with aspirin and clopidogrel, adding 
an oral anticoagulant decreased the incidence of MACE 
(HR: 0.87), but more than doubled the bleeding (HR: 
2.34). The authors concluded that in patients with a recent 
ACS, the addition of a new oral anticoagulant to 
antiplatelet therapy results in a modest reduction in 
MACE but a substantial increase in bleeding, most 
pronounced with triple therapy (Oldgren et al, Eur Heart 
J 2013;34:1670-1680). 
 
CHAMPION PHOENIX: Intravenous Cangrelor 
Significantly Reduced the Rate of Ischemic Events in 
Patients Undergoing PCI 
 
A total of 11,145 patients who were undergoing 
percutaneous coronary intervention (PCI) were randomly 
assigned to receive a bolus and infusion of cangrelor or a 
loading dose of 600 mg or 300 mg of clopidogrel. The 
primary efficacy end point (death, myocardial infarction, 
ischemia-driven revascularization, or stent thrombosis at 
48 hours) occurred in 4.7% in the cangrelor group and 
5.9% in the clopidogrel group (odds ratio-OR, 0.78; 
P=0.005). Stent thrombosis developed in 0.8% in the 
cangrelor group and in 1.4% in the clopidogrel group 
(OR, 0.62; P=0.01); this rate at 48 hours was 0.16% in the 
cangrelor group and 0.11% in the clopidogrel group (OR, 
1.50; P=NS). Adverse events were infrequent except for 
transient dyspnea which occurred more frequently with 
cangrelor (1.2% vs. 0.3%). The authors concluded that 
cangrelor significantly reduced the rate of ischemic 
events, including stent thrombosis, during PCI, with no 
significant increase in severe bleeding (Bhatt et al, N 




STREAM: Prehospital or Early Fibrinolysis Followed 
by Timely Coronary Angiography Resulted in 
Effective Reperfusion in Patients With STEMI 
Presenting Within 3 Hours and Who Could not 
Undergo PCI Within 1 Hour, Albeit With a Slightly 
Increased Risk of Intracranial Bleeding 
A total of 1892 patients with STEMI, who presented 
within 3 hours and who were unable to undergo primary 
PCI within 1 hour, were randomized to primary PCI or 
fibrinolytic therapy (tenecteplase) before transport to a 
PCI-capable hospital. Coronary angiography was 
performed emergently if fibrinolysis failed; otherwise 
within 6-24 hours. The primary end point (death, shock, 
congestive heart failure, or 30-day reinfarction) occurred 
in 116 of 939 patients (12.4%) in the fibrinolysis group 
and in 135 of 943 patients (14.3%) in the primary PCI 
group (relative risk, 0.86; P = NS). Emergency 
angiography was required in 36.3% of patients in the 
fibrinolysis group; the remainder underwent angiography 
at a median of 17 hours. More intracranial hemorrhages 
occurred in the fibrinolysis group (1.0% vs. 0.2%, P = 
0.04; after protocol amendment, 0.5% vs. 0.3%, P = 
0.45). The rates of nonintracranial bleeding were similar. 
The authors concluded that prehospital fibrinolysis with 
timely coronary angiography resulted in effective 
reperfusion in patients with early STEMI who could not 
undergo primary PCI within 1 hour after the first medical 
contact. However, fibrinolysis was associated with a 
slightly increased risk of intracranial bleeding (Armstrong 
et al, N Engl J Med 2013;368:1379-87).  
 
BLOCK HF Trial: Biventricular is Better than Right 
Ventricular Pacing in Patients With AV Block and LV 
Dysfunction With NYHA Class I-III Heart Failure 
A total of 691 patients with AV block requiring 
pacing, NYHA class I-III heart failure and a left 
ventricular (LV) ejection fraction <50% were randomly 
assigned to right ventricular (RV) or biventricular (BiV) 
pacing and were followed for an average of 37 months. 
The primary outcome (death, urgent care visit for heart 
failure requiring IV therapy, or a >15% increase in the 
LV end-systolic volume index) occurred in 190 of 342 
patients (55.6%) in the RV-pacing group, compared with 
160 of 349 (45.8%) in the BiV-pacing group (hazard 
ratio, 0.74). LV lead–related complications occurred in 
6.4% of patients. The authors concluded that BiV pacing 
was superior to conventional RV pacing in patients with 
AV block and LV systolic dysfunction with NYHA class 
I-III heart failure (Curtis et al, N Engl J Med 2013; 
368:1585-1593).  
 
BRUISE CONTROL: No Need to Interrupt Warfarin 
Therapy Before Pacemaker or ICD Implantation 
Patients with an annual risk of thromboembolic events 
of >5% were randomized to continue warfarin or to stop 
it and receive bridging therapy with heparin. The safety 
monitoring committee asked for termination of the trial 
after the second prespecified interim analysis. Clinically 
significant device-pocket hematoma occurred in 12 of 
343 patients (3.5%) in the continued-warfarin group, as 
compared with 54 of 338 (16.0%) in the heparin-bridging 
group (relative risk, 0.19; P<0.001). Major surgical and 
thromboembolic complications were rare and similar in 
the 2 groups (1 tamponade and 1 myocardial infarction in 
the heparin-bridging group and 1 stroke and 1 TIA in the 
continued-warfarin group). The authors concluded that 
compared with bridging therapy with heparin, a strategy 
of uninterrupted warfarin treatment at the time of 
pacemaker or ICD implantation significantly reduced the 
incidence of device-pocket hematomas (Birnie et al, N 
Engl J Med 2013; 368:2084-2093). 
 
ADVANCE III Trial: Using More Intervals to Detect 
Ventricular Tachyarrhythmias Reduces Electrical 
Therapy and Inappropriate ICD Shocks 
A total of 1902 patients (mean age 65 years) with 
ischemic or nonischemic cardiomyopathy receiving an 
implantable cardioverter defibrillator (ICD) for primary 
(75%) or secondary prevention were randomized 1:1 to 
programming with long- (30/40 intervals; n=948) or 
standard-detection (18/24; n=954) intervals. During a 
median follow-up of 12 months, long-detection group had 
346 delivered therapies vs 557 in the standard-detection 
group (incident rate ratio - IRR, 0.63; P<0.001). The 
long- vs the standard-detection group experienced 23 vs 
37 ATPs per 100 person-years (IRR, 0.58; P<0.001); 19 
vs 30 shocks per 100 person-years (IRR, 0.77; P=0.06), 
with a significant difference in the probability of therapy 
occurrence (P<0.001); and a reduction in first occurrence 
of inappropriate shock (5.1 per 100 patient-years vs 11.6; 
IRR, 0.55; P=0.008). Mortality and arrhythmic syncope 
rates did not differ between groups. The authors 
concluded that the use of a long- vs standard-detection 
interval may be preferable as it results in a lower rate of 
electrical therapy, and inappropriate ICD shocks 
(Gasparini et al, JAMA 2013;309:1903-1911).  
 
Receiving a Dual-Chamber ICD for Primary 
Prevention When there is no Indication for Pacing 
Confers Similar Mortality at One Year but a Higher 
Complication Rate  
Among 32,034 patients who received an implantable 
cardioverter defibrillator (ICD) for primary prevention 
and lacked an indication for pacing, 12,246 (38%) 
received a single-chamber and 19,788 (62%) a dual-
chamber device. Rate of complications was lower for 
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single-chamber devices (3.51% vs 4.72%; P<0.001), but 
1-year mortality, 1-year all-cause hospitalization or 
hospitalization for heart failure were similar. The authors 
concluded that when used for primary prevention without 
indication for pacing, dual-chamber ICDs compared with 
single-chamber devices are associated with a higher risk 
of device-related complications and similar 1-year 
mortality and hospitalization outcomes (Peterson et al, 
JAMA 2013;309(19):2025-2034).  
 
Multivessel CABG Confers Lower Long-Term 
Mortality than Multivessel PCI When Comorbidities 
Exist 
Over 5 years of follow-up, among 105,156 propensity 
score–matched patients (aged >65years) with multivessel 
coronary disease undergoing revascularization (1992-
2008), coronary artery bypass surgery (CABG) was 
associated with lower mortality than percutaneous 
coronary intervention (PCI) (hazard ratio-HR, 0.92; 
P<0.001). The difference was greater among patients 
with diabetes (HR, 0.88), tobacco use (HR, 0.82), heart 
failure (HR, 0.84), and peripheral arterial disease (HR, 
0.85). However, patients with none of these factors had 
slightly better survival after PCI. The authors concluded 
that multivessel CABG is associated with lower long-
term mortality than multivessel PCI, an association 
considerably modified by presence of comorbidities, with 
improvement in survival mainly in patients with diabetes, 
tobacco use, heart failure, or peripheral arterial disease 
(Hlatky et al, Ann Intern Med 2013;158:727-734).  
 
ROCKET AF: Patients Transitioned From Warfarin to 
Rivaroxaban Had More Bleeding in First 7 Days Atoned 
After 30 Days  
In ROCKET AF, 7897 (~55%) patients were warfarin-
experienced (at least 6 weeks of prior treatment) and 6367 
(~45%) were warfarin-naive. The effect of rivaroxaban vs 
warfarin on stroke was consistent: 2.32 rates per 100 
patient-years of follow-up vs 2.87 for warfarin-naive 
patients (hazard ratio-HR, 0.81) and 1.98 vs 2.09 for 
warfarin-experienced patients (HR, 0.94; P=NS). During 
the first 7 days, rivaroxaban was associated with more 
bleeding than warfarin (HR in warfarin-naive patients 
5.83, and in warfarin-experienced patients, 6.66). After 
30 days, rivaroxaban had less bleeding than warfarin in 
warfarin-naive patients (HR, 0.84) and similar bleeding in 
warfarin-experienced patients (HR, 1.06; P = 0.003). The 
authors concluded that the efficacy of rivaroxaban in 
warfarin-experienced and warfarin-naive patients was 
similar but there were more bleeding events in the first 7 
days; after 30 days, rivaroxaban was associated with less 
bleeding in warfarin-naive patients and similar bleeding 
in warfarin-experienced patients. Patients enrolled with 
INRs of 2.0-3.0 had outcomes similar to those with INRs 
<2.0. The authors recommend that patients who are going to 
switch from warfarin to rivaroxaban should start 20 mg of 
rivaroxaban and stop warfarin  only when the INR is <3.0 
(Mahaffey et al, Ann Intern Med 2013;158:861-868).  
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(Imazio & Adler, Eur Heart J 2013; 34:1186-1197), 
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